论文部分内容阅读
益赛普(重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白)能竞争性地与血液中TNF-α(肿瘤坏死因子α)结合,阻断它和细胞表面TNF受体结合,降低其活性,减轻炎症反应,从而缓解强直性脊柱炎的临床症状。本文报告13例强直性脊柱炎应用益赛普治疗的观察及护理,11例腰背疼痛、晨僵及外周关节肿痛明显好转,10例血沉及CRP(超敏C反应蛋白)显著降低。通过心理护理、功能锻炼、生活护理,观察用药后的不良反应等一系列护理措施达到较好的临床疗效。
Yisip (recombinant human type II tumor necrosis factor receptor-antibody fusion protein) competitively binds to TNF-α (tumor necrosis factor α) in the blood, blocking its binding to cell-surface TNF receptors and decreasing its activity , Reduce inflammation, thereby relieving the clinical symptoms of ankylosing spondylitis. In this paper, 13 cases of ankylosing spondylitis were treated with Yisipu observation and nursing. Eleven cases of low back pain, morning stiffness and peripheral joint pain were significantly improved, and 10 cases of erythrocyte sedimentation rate and CRP (hypersensitive C-reactive protein) were significantly reduced. Through psychological care, functional exercise, life care, observation of adverse reactions after treatment and a series of nursing measures to achieve better clinical efficacy.